Merck Sharp + Dohme Corp.

Merck Canada Inc.

Jessica Frie

Alexander Pasternak

Haifeng Tang

Shuzhi Dong

Barbara A Pio

Jinlong Jiang

Shawn P Walsh

Fa-Xiang Ding

Zhi-Cai Shi

Xin Gu

Takao Suzuki

Brian Cato

Zhicai Wu

Aurash Shahripour

Qinghong Fu

Yang Yu

Dooseop Kim

Harry R Chobanian

Yan Guo

Timothy Allen Blizzard

Reynalda Keh Dejesus

Reynalda K DeJesus

Tesfaye Biftu

William K Hagmann

Yongxin Han

Bin Hu

Hubert B Josien

Paul E Finke

Ashok Arasappan

Robert S Meissner

Robert R Wilkening

James J Perkins

Iyassu Sebhat

Cheng Zhu

Purakkattle J Biju

Peter J Manley

Helen Y Chen

Christopher W Plummer

Zhengxia Chen

Christopher James Bungard

Kevin Michael Belyk

Scott B Hoyt

Anilkumar G Nair

Kenneth J Leavitt

Zhiqiang Guo

Matthew John Clements

Ming Wang

Ronald Dale Ferguson, Ii

Mingxiang Cui

Zack Zhiqiang Guo

Shouning Xu

Zhifa Pu

Ronald Dale Ferguson

Reynalda K Dejesus

Ronald Dale Ii Ferguson

Reynalda Keh De Jesus

Zhieai Wu

The present invention provides compounds of Formula (I); and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. 

Inhibitors of the renal outer medullary potassium channel

The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R, R, L, X, X, and X, are as defined herein. The compounds of the invention, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising them, are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and may be useful in methods of treating a person in need thereof for diseases or disorders in which the mGluR2-NAM receptor plays a causative role, such as Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders. 

Tetrahydronaphthyridine derivatives as mGluR2-negative allosteric modulators, compositions, and their use

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic tricyclic compounds

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure, kidney disease, edema, and conditions associated with excessive salt and water retention.

This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.

This invention relates to compounds of Formula I-VI having the following general structure: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.

Inhibitors of the Renal Outer Medullary Potassium channel

Growing community of inventors

Harleysville, PA, United States of America

Jessica Frie